(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on developing therapies for serious rare and ultra-rare genetic diseases, on Tuesday reported a narrower loss for the third quarter of 2026, driven by higher revenues and lower research and dev
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.